GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (XSWX:MRK) » Definitions » Cash Flow from Financing

Merck (XSWX:MRK) Cash Flow from Financing : CHF-4,299 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Merck Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Merck paid CHF340 Mil more to buy back shares than it received from issuing new shares. It spent CHF3 Mil paying down its debt. It paid CHF0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent CHF1,602 Mil paying cash dividends to shareholders. It received CHF3 Mil on other financial activities. In all, Merck spent CHF1,941 Mil on financial activities for the three months ended in Dec. 2023.


Merck Cash Flow from Financing Historical Data

The historical data trend for Merck's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cash Flow from Financing Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,706.82 -2,515.95 2,388.15 -8,495.26 -4,159.69

Merck Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,447.71 -1,900.98 3,383.70 -3,840.39 -1,941.48

Merck Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Merck's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Flow from Financing(A: Dec. 2023 )
=Issuance of Stock+Repurchase of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=0+-1164.021+3618.323+0+-6438.436+-175.554
=-4,160

Merck's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-4,299 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck  (XSWX:MRK) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Merck's issuance of stock for the three months ended in Dec. 2023 was CHF0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Merck's repurchase of stock for the three months ended in Dec. 2023 was CHF-340 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Merck's net issuance of debt for the three months ended in Dec. 2023 was CHF-3 Mil. Merck spent CHF3 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Merck's net issuance of preferred for the three months ended in Dec. 2023 was CHF0 Mil. Merck paid CHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Merck's cash flow for dividends for the three months ended in Dec. 2023 was CHF-1,602 Mil. Merck spent CHF1,602 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Merck's other financing for the three months ended in Dec. 2023 was CHF3 Mil. Merck received CHF3 Mil on other financial activities.


Merck Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Merck's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (XSWX:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (XSWX:MRK) Headlines